Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Saudi Pharmaceutical Industries and Medical Appliances Corporation — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,707↑1.5% | 1,682↑1.7% | 1,653↑15.9% | 1,426↓2.3% | 1,460 | |
| Cost of Revenue | 912↑7.9% | 845↓10.6% | 945↑9.9% | 860↑2.4% | 840 | |
| Gross Profit | 795↓5.0% | 837↑18.2% | 708↑25.0% | 566↓8.6% | 620 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00↓100.0% | 76↑107.0% | 37↓13.9% | 43↑428.7% | 8 | |
| General & Administrative Expenses | 0.00↓100.0% | 271↑253.0% | 77↓5.0% | 81↑24.5% | 65 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 333↑243.4% | 97↑24.0% | 78↑8.8% | 72 | |
| SG&A Expenses | 0.00↓100.0% | 604↑247.6% | 174↑9.3% | 159↑16.2% | 137 | |
| Other Expenses | 566↑2732.0% | 20↑240.9% | -14↓103.0% | 476↑9.7% | 434 | |
| Operating Expenses | 566↓19.1% | 700↑13.1% | 619↓8.8% | 678↑17.0% | 579 | |
| Total Costs & Expenses | 1,480↓4.2% | 1,545↓1.2% | 1,564↑1.7% | 1,538↑8.4% | 1,419 | |
| Operating Results | ||||||
| Operating Income | 227↑64.8% | 137↑53.8% | 89↑180.0% | -112↓354.3% | 44 | |
| Depreciation & Amortization | 97↑14.3% | 85↑8.2% | 79↓11.6% | 89↑0.8% | 88 | |
| EBITDA | 324↑45.2% | 223↑28.2% | 174↑1943.6% | -9↓106.6% | 143 | |
| EBIT | 227↑64.2% | 138↑44.6% | 95↑197.1% | -98↓250.9% | 65 | |
| Interest & Other Income | ||||||
| Net Interest Income | -85↑3.7% | -88↓48.9% | -59↓40.1% | -42↓1.2% | -42 | |
| Interest Income | 13↑72.4% | 8 | 0.00↓100.0% | 35↑12.4% | 31 | |
| Interest Expense | 98↑2.4% | 96↑61.8% | 59↑67.8% | 35↑12.4% | 31 | |
| Non-Operating Income | 0.00↑100.0% | -0.54↑91.0% | -6↑55.3% | -13↓39.8% | -10 | |
| Other Income / Expenses | -21↑68.0% | -65↓23.0% | -53↓154.9% | -21↑4.1% | -22 | |
| Income Before Tax | 206↑185.6% | 72↑99.0% | 36↑124.9% | -145↓530.6% | 34 | |
| Income Tax Expense | 9↓77.9% | 40↓11.6% | 45↑81.2% | 25↑102.4% | 12 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 197↑515.0% | 32↑452.6% | -9↑94.9% | -179↓1893.2% | 10 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↓100.0% | 6↑150.9% | -13↓288.5% | -3 | |
| Net Income | 184↑651.6% | 25↑278.9% | -14↑91.9% | -170↓743.5% | 26 | |
| Bottom-Line Net Income | 184↑651.6% | 25↑278.9% | -14↑91.7% | -165↓724.2% | 26 | |
| EPS (Basic) | 1.54↑633.3% | 0.21↑290.9% | -0.11↑92.3% | -1.42↓745.5% | 0.22 | |
| EPS (Diluted) | 1.54↑633.3% | 0.21↑290.9% | -0.11↑92.3% | -1.42↓745.5% | 0.22 | |
| Weighted Average Shares | 120↓0.2% | 120↑0.0% | 120↓0.0% | 120↑0.0% | 120 | |
| Weighted Average Diluted Shares | 120↓0.2% | 120↑0.0% | 120↓0.0% | 120↑0.0% | 120 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.